HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects

Journal of Hepatology

Volumn 57, Issue 6, 2012, Pages 1220-1227

  Klein, Sabine ^a   Van Beuge, Marike Marjolijn ^b   Granzow, Michaela ^a   Beljaars, Leonie ^b   Schierwagen, Robert ^a   Kilic, Sibel ^b   Heidari, Iren ^b   Huss, Sebastian ^a   Sauerbruch, Tilman ^a   Poelstra, Klaas ^b   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Hepatic stellate cells; Intrahepatic resistance; Liver cirrhosis; Portal hypertension; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CARBON TETRACHLORIDE; DESMIN; HUMAN SERUM ALBUMIN; MANNOSE 6 PHOSPHATE; MICROSPHERE; MOESIN; MYOSIN LIGHT CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; HEMODYNAMICS; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; STELLATE CELL; VASCULAR RESISTANCE; WESTERN BLOTTING;

AMIDES; ANIMALS; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PORTAL PRESSURE; PROTEIN KINASE INHIBITORS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES;

EID: 84869222173     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.07.033     Document Type: Article

References (30)

1. W. Ekataksin, and K. Kaneda Liver microvascular architecture: an insight into the pathophysiology of portal hypertension Semin Liver Dis 19 1999 359 382
2. M. Hennenberg, J. Trebicka, T. Sauerbruch, and J. Heller Mechanisms of extrahepatic vasodilation in portal hypertension Gut 57 2008 1300 1314
3. J. Trebicka, M. Hennenberg, W. Laleman, N. Shelest, E. Biecker, and M. Schepke Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase Hepatology 46 2007 242 253
4. J. Trebicka, L. Leifeld, M. Hennenberg, E. Biecker, A. Eckhardt, and N. Fischer Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats Hepatology 47 2008 1264 1276
5. M. Hennenberg, E. Biecker, J. Trebicka, K. Jochem, Q. Zhou, and M. Schmidt Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats Gastroenterology 130 2006 838 854
6. M. Hennenberg, J. Trebicka, E. Biecker, M. Schepke, T. Sauerbruch, and J. Heller Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins Hepatology 45 2007 495 506
7. Q. Zhou, M. Hennenberg, J. Trebicka, K. Jochem, L. Leifeld, and E. Biecker Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis Gut 55 2006 1296 1305
8. C.J. Steib, M. Hennenberg, F. Beitinger, A.C. Hartmann, M. Bystron, and E.N. De Toni Amiloride reduces portal hypertension in rat liver cirrhosis Gut 59 2010 827 836
9. M. Schepke, J. Heller, S. Paschke, J. Thomas, M. Wolff, and M. Neef Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism Hepatology 34 2001 884 888
10. J. Bosch, and J.C. Garcia-Pagan Complications of cirrhosis. I. Portal hypertension J Hepatol 32 2000 141 156
11. S.L. Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 2008 1655 1669
12. P.J. de Bleser, P. Jannes, S.C. van Buul-Offers, C.M. Hoogerbrugge, C.F. van Schravendijk, and T. Niki Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells Hepatology 21 1995 1429 1437
13. R. Greupink, H.I. Bakker, H. van Goor, M.H. de Borst, L. Beljaars, and K. Poelstra Mannose-6-phosphate/insulin-Like growth factor-II receptors may represent a target for the selective delivery of mycophenolic acid to fibrogenic cells Pharm Res 23 2006 1827 1834
14. T. Gonzalo, E.G. Talman, A. van de Ven, K. Temming, R. Greupink, and L. Beljaars Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology J Control Release 111 2006 193 203
15. L. Beljaars, G. Molema, B. Weert, H. Bonnema, P. Olinga, and G.M. Groothuis Albumin modified with mannose 6-phosphate: a potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells Hepatology 29 1999 1486 1493
16. M.M. van Beuge, J. Prakash, M. Lacombe, R. Gosens, E. Post, and C. Reker-Smit Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice J Pharmacol Exp Ther 337 2011 628 635
17. M.M. van Beuge, J. Prakash, M. Lacombe, E. Post, C. Reker-Smit, and L. Beljaars Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632 Pharm Res 28 2011 2045 2054
18. L. Beljaars, P. Olinga, G. Molema, P. de Bleser, A. Geerts, and G.M. Groothuis Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin (M6P(28)-HSA) Liver 21 2001 320 328
19. J. Prakash, M.H. de Borst, M. Lacombe, F. Opdam, P.A. Klok, and H. van Goor Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury J Am Soc Nephrol 19 2008 2086 2097
20. J. Trebicka, M. Hennenberg, A. Schulze Probsting, W. Laleman, S. Klein, and M. Granzow Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis Hepatology 50 2009 1924 1935
21. J.P. Hakkinen, M.W. Miller, A.H. Smith, and D.R. Knight Measurement of organ blood flow with coloured microspheres in the rat Cardiovasc Res 29 1995 74 79
22. J. Heller, T. Shiozawa, J. Trebicka, M. Hennenberg, M. Schepke, and M. Neef Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats Eur J Clin Invest 33 2003 1006 1012
23. J. Heller, J. Trebicka, T. Shiozawa, M. Schepke, M. Neef, and M. Hennenberg Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis Liver Int 25 2005 657 666
24. E. Biecker, J. Trebicka, A. Kang, M. Hennenberg, T. Sauerbruch, and J. Heller Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension Liver Int 28 2008 331 338
25. M. Hennenberg, J. Trebicka, D. Buecher, J. Heller, and T. Sauerbruch Lack of effect of norfloxacin on hyperdynamic circulation in bile duct-ligated rats despite reduction of endothelial nitric oxide synthase function: result of unchanged vascular Rho-kinase? Liver Int 29 2009 933 941
26. M. Hennenberg, J. Trebicka, C. Stark, A.Z. Kohistani, J. Heller, and T. Sauerbruch Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis Br J Pharmacol 157 2009 258 270
27. L. Moleda, J. Trebicka, P. Dietrich, E. Gabele, C. Hellerbrand, and R.H. Straub Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction Gut 60 2011 1122 1132
28. J.G. Geraghty, W.J. Angerson, and D.C. Carter Portal venous pressure and portasystemic shunting in experimental portal hypertension Am J Physiol 257 1989 G52 G57
29. R. Bataller, and D.A. Brenner Liver fibrosis J Clin Invest 115 2005 209 218
30. S.S. Lee, J. Marty, J. Mantz, E. Samain, A. Braillon, and D. Lebrec Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats Hepatology 12 1990 481 485